

OraMod project

Helping clinicians predict oral cavity cancer reoccurrence

Genomic markers and models can predict the reoccurrence of oral cavity cancer. But these innovative diagnostic technologies are currently stuck in labs and are not being used by clinicians in hospitals. The EU-funded project OraMod, led by University of Parma, aims to solve this problem by building an IT platform and a diagnostic device.



OraMod continues the research conducted by the finished FP7-NeoMark project: NeoMark produced a set of prognostic bio-markers and a genetic bio-signature significant for reoccurrence of oral cavity tumors - a disease more and more frequent and with a very high mortality rate. By adopting the results of the most advanced research in oncology and of technology developments in the fields of genomics, image diagnostics and biostatistical predictive models, the project experts will provide to clinicians a technology platform allowing the early identification of patients at highest risk of bad prognosis.

Analysing data

The platform will be able to analyse tens of thousands clinical, radiology and genomic data for each individual patient. It will be able to detect the patients at high risk for disease reoccurrence, for whom personalized and specific therapeutic approaches will be adopted.

Low-cost identification

An innovative in vitro **diagnostic device** based on a personalized "lab-on-chip" will allow fast and low-cost identification of genomic predictive markers. The OraMod project will receive a funding of more than € 3 million throughout three years. It engages 8 partners from 5 European countries, among which:

- three university hospitals (VU medical center Amsterdam, Heinrich-Heine University Clinic Dusseldorf and the University of Parma with the University Hospital);
- two primary European research institutions (the Fraunhofer Institute for Computer Graphics IGD Darmstad Germany and the VTT Technology Center of Finland);
- three technology providers (Velti in Greece, OneToNet and STmicroelectronics in Italy).

The OraMod project will receive a funding of more than € 3 million throughout three years. It engages 8 partners from 5 European countries, among which:

- | | |
|---|----------------------------------------|
| 3 | University hospitals |
| 2 | Primary European research institutions |
| 3 | Technology providers |

[http://www.](http://www.oramod.eu)

www.oramod.eu



OraMod project has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 611425